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Abstract The objective of this study was to assess the safety
of adalimumab in patients aged 2 to <4 years old or ≥4 years
old weighing <15 kg with moderately to severely active
polyarticular juvenile idiopathic arthritis (JIA). Clinical effec-
tiveness and pharmacokinetics (PK) of adalimumab were also
evaluated. This was an international, multicenter, open-label,
phase 3b study in 32 patients with active JIA that were treated
with adalimumab 24 mg/m2 (maximum=20 mg/dose) every
other week up to 120 weeks, with or without concomitant
methotrexate. Adverse events (AEs) were summarized for
completed visits. Efficacy endpoints included American Col-
lege of Rheumatology pediatric (PedACR) 30/50/70/90 re-
sponses and JIA core components. Adalimumab serum trough
concentrations were measured in a subset of patients. Among
the patients, 88 % were female. Baseline mean age, weight,
and JIA duration were 3 years, 13 kg, and 12 months, respec-
tively; 39 % had elevated C-reactive protein. AE incidence
rates included any AEs (29/32, 91 %), serious AEs (5/32,
16 %), infectious AEs (25/32, 78 %), and serious infections
(3/32, 9 %). No deaths, malignancies, or opportunistic infec-
tions were reported. Growth was not adversely impacted. At
week 96, 92 % of patients achieved PedACR30, and 77 %
achieved PedACR70. Improvements in JIA core components
were observed. Mean steady-state serum adalimumab trough
concentrations were 7–8 μg/mL at weeks 12 and 24.
Adalimumab was well tolerated in JIA patients aged 2 to
<4 years old or ≥4 years old weighing <15 kg. The efficacy
and PK of adalimumabwere comparable to those seen in older
JIA patients.
Keywords Adalimumab . Polyarticular juvenile idiopathic
arthritis . Safety
Introduction
Juvenile idiopathic arthritis (JIA), the most common rheumat-
ic disease of childhood, comprises a group of autoimmune
diseases that often persists into adulthood with the potential
for generating significant disability and growth impairment
[1]. JIA has an estimated incidence of 15 per 100,000 and is
2.5 times more common in female patients [2, 3]. For the
subset diagnosed with polyarticular onset/course JIA, defined
as arthritis affecting ≥5 joints, the age of onset has a bimodal
distribution, with peak incidences at 2–4 years and 10–
14 years [2].
The antimetabolic agent, methotrexate (MTX), is common-
ly used in the treatment of polyarticular JIA; however, not all
patients respond sufficiently to MTX, and some are intolerant
of its side effects. The newer biologic agents, such as tumor
necrosis factor (TNF) inhibitors, represent an advancement in
the management of JIA, particularly for children who cannot
achieve adequate disease control with traditional antirheumat-
ic treatments; however, the effects of these agents in very
young children with JIA (age <4 years) are not well
understood.
Adalimumab is a fully human anti-TNF antibody that is
approved for use in moderate to severe polyarticular JIA in
patients ≥4 years of age in the US, EU, and Japan [4–6], and as
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of February 2013, adalimumab was also approved in EU for
use in patients aged 2 to <4 years old [6]. Adalimumab has
been shown to be safe and effective in JIA patients aged 4–
17 years when dosed every other week (eow), [7] and in an
international trial, clinical responses with adalimumab were
maintained for up to 6 years [8]. Similar results were observed
in a pediatric Japanese JIA population through 60 weeks of
treatment [9]. However, adalimumab has not been systemati-
cally studied in patients <4 years of age, and limited data are
available for patients ≥4 years of age who weigh <15 kg.
This study examined the safety of adalimumab in a very
young JIA population with active polyarticular disease. Pa-
tients could be enrolled with or without concurrent MTX use
and were to receive adalimumab for a minimum of 24 weeks.
The primary objective of this report is to summarize the safety
of adalimumab in this population over the course of the study;




Eligible patients were aged 2 to <4 years or aged ≥4 years and
weighing <15 kg with moderately to severely active
polyarticular or polyarticular course JIA, as defined per the
International League of Associations for Rheumatology
(ILAR) criteria. Patients had moderately to severely active
disease with ≥5 active joints at the time of study entry. In
addition, in EU, patients must have previously failed, had an
insufficient response to, or been intolerant of at least one
DMARD, consistent with the local prescribing information
for adalimumab in older children. Main study exclusion
criteria were prior exposure to a TNF inhibitor or other bio-
logic therapy, joint surgery within 2 months of screening (of
joints to be assessed within the study), chronic recurring
infection or active tuberculosis (TB), or significant concomi-
tant illness. A parent or legal guardian provided written in-
formed consent before any study procedures were performed.
Study design
This was an international, multicenter, open-label, phase 3b
study (trial registration: NCT00775437) conducted at 14 sites
in the US and the EU. A central institutional review board or
independent ethics committee approved the study at each site;
the study was conducted in accordance with the International
Conference on Harmonization good clinical practices and the
Declaration of Helsinki. Prior to any study-related procedures,
the informed consent statement was reviewed, signed, and
dated by the patient’s parent. The size of the study was
determined based upon a commitment to the US Food and
Drug Administration (FDA) to provide safety and efficacy
data for adalimumab when used in 2 to <4 year old patients
with JIA, and, in accordance with the FDA, the proposed
sample size for this study was approximately 30 patients.
Qualified patients received adalimumab subcutaneously
(24 mg/m2, maximum 20 mg/dose) eow for a minimum of
24 weeks in a clinical setting. The continuation of prior JIA
treatments, such as MTX, stable doses of nonsteroidal anti‐
inflammatory drugs (NSAIDs) and/or low-dose corticoste-
roids (equal to prednisone ≤0.2 mg/kg/day) was permitted.
In the US, patients could continue in the study until reaching
age 4 and ≥15 kg; in EU, patients could continue in the study
for up to 1 additional year after reaching age 4 and ≥15 kg to
allow time to transition to an appropriate treatment. Upon
completion of the study, patients who transitioned to commer-
cially available adalimumab were offered the chance to partic-
ipate in a long-term JIA registry (STRIVE, NCT00783510).
Patients had a screening visit, baseline visit, and visits at weeks
2, 4, 8, 12, 16, 20, and 24. Visits occurred every 12 weeks for
patients who continued in the study after week 24.
Safety
Adverse events (AEs), serious adverse events (SAEs), and
events of special interest were collected throughout the
study. Severe adverse events were events that caused
considerable interference with the patient’s usual activities
and may be incapacitating or life-threatening, though not
considered an SAE. In contrast, SAEs include those that
met any of the following criteria: death, life-threatening
(i.e., would have resulted in immediate fatality without
medical intervention), hospitalization, prolongation of hos-
pitalization, persistent or significant disability, or any im-
portant medical event requiring medical or surgical inter-
vention to prevent serious outcome. Patients were also
monitored for SAEs/AEs for up to 70 days after their last
dose of study medication or until they began commercial
adalimumab, whichever came first. Laboratory assessments
for chemistry, hematology, and serology were taken at
baseline, weeks 12, 24, and every 12 weeks thereafter,
including the final study visit.
Efficacy measures
As secondary study endpoints, American College of Rheuma-
tology pediatric (PedACR) 30/50/70/90 responses were deter-
mined at each visit, defined as at least 30 %, 50 %, 70 %, and
90% improvement, respectively, from baseline in any three of
the six following JIA core set variables, with worsening of
≥30 % in not more than one of the criteria: (1) Physician’s
Global Assessment of Disease Activity (PhGA; 0–100 mm
visual analog scale [VAS]); (2) Parent’s Global Assessment of
Disease Activity (PaGA; 0–100 mm VAS); (3) functional
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ability as measured by the Disability Index of the Childhood
Health Assessment Questionnaire (DI-CHAQ); (4) number of
joints with active arthritis (AJC) in 73 joints; (5) number of
joints with limitation of motion (LOM) in 69 joints; and (6)
laboratory marker of inflammation, C-reactive protein (CRP)
level. Other joint assessments included tender joint count
(TJC) in 75 joints, swollen joint count (SJC) in 66 joints,
and pain on passive motion (POM) in 75 joints. Parent’s
Global Assessment of Pain (PaGA of Pain [0–100 mm
VAS]) was also summarized. Patient height and weight were
measured at baseline and at specified study visits. Addition-
ally, patients were grouped by baseline height into four cate-
gories: <5th, ≥5th – <25th, ≥25th – <50th, and ≥50th percen-
tile based on the US Centers for Disease Control and Preven-
tion (CDC) growth charts. Mean CDC percentile changes in
height and weight were calculated through 96 weeks. Patients
may also have been evaluated for inactive disease, defined by
the following criteria: no active arthritis, fever, rash, serositis,
splenomegaly, generalized lymphadenopathy attributable to
JIA, or JIA-associated uveitis, in addition to normal CRP level
and PhGA indicating clinical disease quiescence.
Pharmacokinetics
Per protocol, blood samples were provided by a subset of the
study population (n=15) to be analyzed for serum
adalimumab concentrations and anti-adalimumab antibodies
(AAA) at baseline and weeks 12 and 24 using a validated
enzyme-linked immunosorbent assay.
Statistical analyses
The intent-to-treat (ITT)/safety population included all pa-
tients who had received at least one dose of adalimumab.
Safety data are summarized up to 120 weeks of treatment:
AEs are reported as number and percentage of patients affect-
ed and as events per 100 patient-years (E/100 PYs). Efficacy
data are presented based on observed values (weeks 12, 24,
60, and 96) and nonresponder imputation (NRI) (weeks 12
and 24). Growth data was analyzed as observed.
Results
Patient disposition
A total of 32 patients were enrolled (15 from the US and 17
from the EU), and all received ≥1 dose of adalimumab, with
31 patients (97 %) completing 24 weeks of treatment (Fig. 1).
Two patients withdrew prior to week 60, while one patient
withdrew from the study at the week 60 visit. Three additional
patients discontinued the study after week 60. Twenty-six
patients (81 %) completed the study after achieving age and
weight termination criteria, with 13 patients completing week
96 and three patients completing week 120.
Baseline demographics, disease characteristics, and prior
and concomitant therapies
Most patients were female and white (Table 1). The mean age
at baseline was 3 years, with a mean JIA disease duration of 12
months. Baseline disease activity was consistent with moder-
ately to severely active polyarticular JIA, with a mean AJC of
10.0. At baseline, 39 % had elevated CRP (≥0.9 mg/dL), 18
patients were ANA positive, and one patient was rheumatoid
factor positive (RF+). Baseline JIA onset types by ILAR
criteria were RF-negative polyarthritis (20/32, 62.5 %), ex-
tended oligoarthritis (8/32, 25 %), systemic onset with
polyarticular course arthritis (2/32, 6.3 %), RF+ polyarthritis,
and undifferentiated arthritis (1/32, 3.1 %) each.
Most patients (25/32, 78 %) had received MTX as a prior
JIA therapy. The majority of patients (27/32, 84 %) took
concomitant MTX during the study; of these, 59 % received
concomitant folic acid. Only one patient (3 %) took concom-
itant hydroxychloroquine, while the remainder of the patients
did not receive concomitant DMARDs. Approximately 63 %
of patients reported use of systemic corticosteroids for their
JIA, and 56 % reported use of NSAIDs during the study. A
total of 31 patients (97 %) took at least one non-rheumatic
medication during the study, with folic acid, standard child-
hood vaccines, paracetamol, and amoxicillin being reported
most frequently.
Safety
Safety data are summarized for all patients up to 120 weeks of
treatment. Mean duration (SD) of adalimumab exposure was
515 (245) days; all subjects had at least 57 days of
adalimumab exposure, with a maximum exposure of 910
days. This analysis represents approximately 45.1 PYs of
exposure to adalimumab.
A total of 29 patients (90.6 %) reported at least one AE
(Table 2). The most frequently reported AEs (occurring in
≥10 % of patients) were nasopharyngitis (n=8, 25 %), pyrexia
(n=7, 22 %), bronchitis, cough, rhinorrhea, and upper respi-
ratory infection (n=6 each, 19 %), otitis media, worsening of
rheumatoid arthritis (JIA), and vomiting (n=5 each, 16 %),
and diarrhea, gastroenteritis, rash, and rhinitis (n=4 each,
13 %), regardless of investigator’s assessment for any rela-
tionship to study drug. Two patients discontinued the study
due to an AE (worsening of JIA and loss of efficacy with JIA
flare). While a majority of patients had nonserious events, five
patients were reported to have one SAE each, which included
dental caries, gastroenteritis rotavirus, worsening of JIA, type
1 diabetes mellitus, and varicella; these were considered to be
“not related” or “probably not related” to adalimumab by the
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investigators. All SAEs were considered to be mild or mod-
erate with the exception of diabetes mellitus (new onset, type
1), which was considered to be severe.
Regarding AEs of special interest with respect to TNF
blockade, there were no cases of congestive heart failure-
related AEs, demyelinating disease, lupus-like syndrome, ma-
lignancies, opportunistic infections/TB, blood dyscrasias, or
deaths. The only AEs of special interest reported in this study
were infections (serious and nonserious) and injection site-
related AEs. The most frequently reported infections (≥10 %
of patients) were nasopharyngitis, upper respiratory tract in-
fection, bronchitis, otitis media, rhinitis, and gastroenteritis.
Most infections were mild or moderate; one patient was
reported to have a severe event (otitis media). All but five
patients had infections that were considered to be “not related”
or “probably not related” to adalimumab by the investigator.
In these five patients, bronchitis, cystitis, ear infection, laryn-
gitis, otitis media, pharyngitis, pneumonia, and viral pharyn-
gitis were deemed as “possibly” or “probably related” to study
drug by the investigator. Three patients had infections that
were reported as serious (one case each of dental caries,
gastroenteritis rotavirus, and varicella). All three serious in-
fections were considered by the investigator as “not related” to
adalimumab and were mild or moderate in severity; all three
subjects continued their participation in the study. Injection
site-related events considered “probably related” to
adalimumab were reported for four patients (injection site
pain, injection site pruritus and swelling, injection site rash,
Fig. 1 Patient disposition
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and unspecified injection site reaction) but were considered to
be mild and did not affect study participation.
Growth, as measured by height and weight, was not ad-
versely affected by adalimumab treatment in these children
(Fig. 2). Mean change (SD) from baseline to week 60 was +
9.5 cm (2.34) for height (Fig. 2a) and +2.66 kg (0.98) for
weight (Fig. 2b) and at week 96 was +15.2 cm (3.48) for
height and +4.38 kg (1.44) for weight. Among the 32 patients,
only one (3.1 %) was in the <5th percentile based on the CDC
growth charts and had a −0.03 % and 2.4 % change in mean
height and weight percentiles, respectively. Patients had a 5.6,
24.9, and 18.2 % change in mean height percentile for ≥5th –
<25th, ≥25th – <50th, and ≥50th percentile, respectively,
through 96 weeks of ADA treatment (Fig. 2c). Similarly, there
was a 10.2, 8.1, and 25.5 % change in mean weight per-
centile for ≥5th – <25th, ≥25th – <50th, and ≥50th
percentile, respectively (Fig. 2d).
Efficacy
The percentage of patients with PedACR30 responses at
weeks 12, 24, 60, and 96 were 94 %, 90 %, 90 %, and
92 %, respectively (Fig. 3a); PedACR50/70/90 responses at
weeks 12, 24, 60, and 96 were 90 %/61 %/39 %, 83 %/73 %/
37 %, 80 %/70 %/50 %, and 92 %/77 %/62 %, respectively.
Additionally, all three subjects completing week 120 had a
good and sustained response achieving PedACR90. PedACR
response rates at weeks 12 and 24, using NRI method, were
similar to rates in the observed case analysis (Fig. 3b).
Statistically significant improvements from baseline in the
JIA core variables (PhGA, PaGA, DI-CHAQ, AJC, and
LOM), joint assessments (TJC75, SJC66, and POM75), and
PaGA of pain were observed with adalimumab treatment at
weeks 12, 24, 60, and 96 weeks (Table 3). Mean CRP im-
proved from baseline to weeks 12, 24, and 60 but did not
achieve statistical significance.
Pharmacokinetics
Mean steady-state serum adalimumab trough concentrations
were measured at weeks 12 and 24 and were found to be
consistent with levels achieved in older children (age 4–17)





Age, years 3.0 (0.72)
Female, n (%) 28 (87.5)
White, n (%) 25 (78.1)
Weight, kg 13.4 (2.0)
Height, cm 93.0 (5.8)
Duration of JIA, months 12.3 (9.3)
Disease characteristics
PedACR core variables
PhGA (VAS) 55.3 (19.70)
PaGA (VAS) 47.6 (25.91)
DI-CHAQ (0–3) 1.2 (0.66)
AJC73 10.0 (7.47)
LOM69 8.6 (7.69)
CRP, mg/dLa 1.6 (2.43)
Other variables
CRP <0.9 mg/dL, n (%)a 19 (61.3)
ANA positive, n (%) 18 (56.3)
RF positive, n (%) 1 (3.1)
Prior JIA therapies
Methotrexate, n (%) 25 (78.1)





Methotrexate, n (%) 27 (84.4)
NSAIDs, n (%) 18 (56.3)
Systemic corticosteroids, n (%)b 20 (62.5)
All values are expressed as the mean (standard deviation), unless indicat-
ed otherwise. a n=31. b Systemic corticosteroids include oral, injected,
and rectal preparations and do not include nonsystemic preparations
(ophthalmologicals, dermatologicals, and inhalants)
AJC active joint count, CRP C-reactive protein (<0.9 mg/dL=normal),
DI-CHAQDisability Index Childhood Health Assessment Questionnaire,
JIA juvenile idiopathic arthritis, LOM limitation of motion, NSAID non-
steroidal anti-inflammatory drug, PaGA Parent’s Global Assessment,
PhGA Physician’s Global Assessment, RF rheumatoid factor, VAS visual
analog scale of 0–100 mm
Table 2 Overview of adverse events (AEs)
N=32 PYs=45.1
n (%) E (E/100 PYs)
Any AE 29 (90.6) 217 (481)
At least “possibly drug
related” per the investigator
11 (34.4) 22 (48.8)
Severe AE 6 (18.8) 6 (13.3)
Serious AEa 5 (15.6) 5 (11.1)
AE leading to discontinuation
of study drugb
2 (6.3) 2 (4.4)
Infectious AEc 25 (78.1) 93 (206)
Serious infectious AEd 3 (9.4) 3 (6.7)
Injection site-related AE 4 (12.5) 6 (13.3)
E number of events, PYs patient-years. a Serious AEs included dental
caries, gastroenteritis rotavirus, worsening of JIA, type 1 diabetes
mellitus, and varicella. b AEs leading to discontinuation of study drug
were worsening of JIA and JIA flare. c No opportunistic infections or
cases of TB were reported. d Three patients had infections that were
categorized as serious (one case each of dental caries, rotavirus gastroen-
teritis, and varicella virus)
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with JIA (7). In the current study, adalimumab trough concen-
trations were noted to be numerically higher in patients who
received concomitant MTX (7–8 μg/mL) compared to those
who did not (6 μg/mL), but there were too few patients (n=4)
in the non-MTX group to allow statistical analysis. In addi-
tion, correlation of pharmacokinetics with efficacy data could
not be performed due to the small sample size. Among the 15
patients who had samples for pharmacokinetic analysis, only
one patient (6.7 %) developed AAA+during the 24 weeks that
were evaluated.
Discussion
Treatment with adalimumab has been shown to significantly
improve the signs and symptoms of active polyarticular JIA in
patients aged 4 to 17 years [7, 9]. Limited data are available on
the use of TNF inhibitors in children with JIA who are
younger than 4 years of age, and no previous studies have
evaluated the safety of adalimumab in this population. The
objectives of this phase 3b open-label study were to system-
atically evaluate the safety, effectiveness, and pharmacokinet-
ics of adalimumab in children with JIA aged 2 to <4 years or
≥4 years weighing <15 kg. Overall, adalimumab was well
tolerated and efficacious in this very young patient population.
Regarding the safety profile, infections were the most
commonly reported AEs. No cases of opportunistic infection
or TB occurred in up to 120 weeks of adalimumab treatment,
but one SAE of varicella infection was reported, consistent
with incidence data from other studies [10, 11]. New onset
type I diabetes mellitus developed in one patient and was
reported as an SAE, but considered “not related” to study
drug by the investigator. Although a relationship between
adalimumab and type I diabetes mellitus cannot be exclu-
ded [12–14], the patient’s father also has type I diabetes
mellitus, possibly providing the basis for additional genetic
Fig. 2 Mean change from baseline in growth over time. aMean change
in height+standard deviation (SD) in centimeters (cm) over 96 weeks of
adalimumab treatment. b Mean change in weight+standard deviation
(SD) in kilograms (kg) over 96 weeks of adalimumab treatment. cMean
height percentile change from baseline over 96 weeks of adalimumab
treatment in <5th, ≥5th – <25th, ≥25th – <50th, and ≥50th percentile
based on the US Centers for Disease Control and Prevention (CDC)
growth charts. dMean weight percentile change from baseline over 96
weeks of adalimumab treatment in <5th, ≥5th – <25th, ≥25th – <50th, and
≥50th percentile based on the US Centers for Disease Control and
Prevention (CDC) growth charts. Observed analysis
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susceptibility for diabetes mellitus in the patient. Additionally,
it is well known that there are increased risk and frequency of
type I diabetes mellitus developing in patients with JIA [15,
16]. Another SAE, recorded as “not related” to study drug,
involved a child with preexisting dental caries who required
hospitalization for a sedated dental procedure. The prevalence
of injection site reactions (4/32, 12.5 %) was notably lower
than in previous literature. Although injection site reactions
are not uncommon, the low number of reactions recorded in
this study may be reflective of reporting practices more than
event rates. During 45.1 PYs of adalimumab exposure, no
patients were withdrawn due to an SAE; however, two pa-
tients discontinued the study due to nonserious AEs (“wors-
ening of JIA” and “JIA flare”).
With respect to AEs of special interest, there were no
reports of congestive heart failure-related AEs, demyelinating
disease, lupus-like syndrome, malignancies, opportunistic
infections/TB, allergic reactions, blood dyscrasias, or deaths.
Moreover, no safety events were identified that were unique to
this young population, and the findings were similar to those
obtained in trials of older pediatric patients [7, 9] and in adults
with rheumatoid arthritis (RA) [17]. The safety profile was, in
fact, very comparable to another study by Imagawa et al. [9]
that evaluated the efficacy and safety of adalimumab in pa-
tients aged 4–17 years with JIA in Japan. Six out of 25 patients
(24 %) in the Japanese study had an SAE, compared to 15.6%
in this study. Similarly, 21 (84 %) versus 25 (78.1 %) had
infections, and 3 (12 %) versus 3 (9.4 %) had reported serious
infections in the Japanese study and our study, respectively.
Growth parameters are of particular interest in this very
young patient population, given the potential negative impact
of chronic, active JIA, and standard therapies (such as corti-
costeroids) on normal childhood development [18]. In this
study, height and weight measurements over time revealed
Fig. 3 PedACR 30/50/70/90
response rates over time. a
Percentage of patients achieving
PedACR 30/50/70/90 responses
at weeks 12, 24, 60, and 96.
Observed analysis. b Percentage
of patients achieving PedACR 30/
50/70/90 responses at weeks 12
and 24. Nonresponder imputation
(NRI)
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that treatment with adalimumab did not adversely impact
growth in this age group.
Although not the primary endpoint, results of this study
also demonstrated the efficacy of adalimumab in improving
clinical response and reducing disease activity in very young
patients with JIA. A comparison of the PedACR response
rates between the patients in this study and older children in
prior JIA trials [7, 9] shows that similar, high rates of favorable
clinical responses occurred in both age groups. Furthermore,
treatment with adalimumab in all three of these JIA studies led
to sustained improvement in JIA core components and other
efficacy parameters. These findings are also consistent with
those observed in adult RA studies [19, 20].
Serum adalimumab trough concentrations obtained in a
subset of this study population showed that the mean steady-
state adalimumab levels were within the range observed in
children with JIA aged 4 to 17 years [7] and were consistent
with levels observed in other adalimumab trials [21, 22].
Although mean adalimumab levels were numerically higher
in patients who received concomitant MTX therapy, the small
number of patients in the non-MTX arm (n=4) makes it
difficult to draw conclusions regarding the impact of MTX
on adalimumab concentrations in this population. Importantly,
the results demonstrate that steady-state levels of adalimumab,
considered to be therapeutic, can be achieved with or without
MTX in this very young JIA population. Additional serologic
testing identified only one of 15 patients (6.7 %) with AAA,
and due to the very small sample size, no conclusions regard-
ing the effect of AAA on safety or efficacy could be made.
Limitations of this study include the open-label nature, the
small number of patients, the indirect measurement of pain
(via parent assessment), the limited length of follow-up to
date, which does not allow conclusions to be made about
long-term side effects and safety, and lack of assurance that
responders could continue receiving adalimumab upon com-
pletion of the study. In the US, patients could transition to
commercially available adalimumab after the age of 4 and
achieving weight ≥15 kg. In the EU, patients were allowed to
continue study treatment with adalimumab for up to 1 addi-
tional year after achieving the age of 4 and ≥15 kg, providing
time necessary to transition to medication until the local
approval was obtained for treatment continuation. All patients
continuing on commercial adalimumab after study completion
were offered the opportunity to enroll into a long-term JIA
registry, and 12 patients (37.5 %) transitioned from the study
to the JIA registry. Even so, despite these limitations, the
results described herein are in agreement with results obtained
in other JIA studies of adalimumab safety and efficacy [7, 9].
In summary, the results suggest that adalimumab is a well-
tolerated treatment option with or without concurrent MTX in
patients with active polyarticular JIA who are aged 2 to
<4 years or ≥4 years weighing <15 kg. No new safety signals
occurred in this study. There were no events of opportunistic
infections/TB,malignancies, or deaths reported, and the safety
of adalimumab in this patient population was comparable to
that observed in older JIA patients. Adalimumab was also
efficacious in this younger patient population, resulting in
high and sustained clinical responses for up to 96 weeks.












PhGA (VAS) 55.3 (19.70) −41.4 (21.20)* −45.3 (21.32)* −42.7 (28.17)* −47.5 (24.42)*
PaGA (VAS) 47.6 (25.91) −28.1 (29.91)* −32.2 (29.74)* −34.5 (33.31)* −45.8 (29.10)*
DI-CHAQ (0–3) 1.2 (0.66) −0.5 (0.64)** −0.5 (0.69)** −0.6 (0.71)** −0.8 (0.56)*
AJC73 10.0 (7.47) −7.3 (4.52)* −7.2 (5.60)* −9.5 (7.50)* −8.9 (7.04)*
LOM69 8.6 (7.69) −5.6 (4.80)* −5.6 (5.54)* −5.5 (8.31)** −7.5 (6.73)**
CRP, mg/dLa 1.6 (2.43) −0.6 (2.65) −0.2 (3.20) −0.3 (1.83) 0.1 (1.60)
Other assessments
TJC75 3.8 (5.02) −2.7 (5.09)** −3.0 (5.54)** −4.5 (5.85)** −4.0 (5.46)**
SJC66 8.9 (7.37) −6.2 (4.24)* −6.3 (5.83)* −8.4 (7.15)* −8.5 (6.89)*
POM75 5.3 (4.66) −4.9 (4.59)* −4.1 (7.32)** −5.9 (5.25)* −5.7 (5.12)**
PaGA of pain (VAS) 46.1 (25.73) −27.2 (25.36)* −29.5 (28.28)* −35.2 (34.40)* −45.1 (26.45)*
AJC active joint count, CRP C-reactive protein, DI-CHAQ Disability Index Childhood Health Assessment Questionnaire, LOM limitation of motion,
PaGA Parent’s Global Assessment, PhGA Physician’s Global Assessment, POM pain on motion, SJC swollen joint count, TJC tender joint count, VAS
visual analog scale of 0–100 mm
*P<0.001; **P<0.05. The t test was used to calculate statistical significance, and all values are expressed as the mean (standard deviation)
a n=31 at baseline, n=28 at weeks 12 and 24, n=20 at week 60, and n=12 at week 96
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Taken together, these results provide the first clinical trial data
on the effects of adalimumab for the treatment of moderately
to severely active JIA in this very young population.
Key points
& Adalimumab therapy with or without methotrexate was
safe and well tolerated in this very young population, with
outcomes comparable to those observed in older JIA
patients treated with adalimumab
& Adalimumab proved efficacious with sustained improve-
ment of core JIA disease activity parameters for 96 weeks
of therapy
& These novel data represent the first systematic clinical trial
results reported for adalimumab therapy in this very young
population with JIA, a group with significant unmet med-
ical need
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